Assembly Biosciences is a clinical stage biotechnology company which develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The Company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions, and a patent pending delivery system, GEMICEL.